Summary
In this project, we will evaluate the use and performance of a CE-marked device (wearable), which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability for the purpose of early detection and monitoring of COVID-19 in general and high-risk populations. At the same time, a mobile application will be used to track participant-reported symptoms. A prospective, observational study will follow 13,000 individuals from the general population and 7,000 high-risk individuals wearing the device and responding to participant self-report parameters via a purpose-designed app. Based on this data, an algorithm will indicate which individuals likely require general practitioner (GP) care (for COVID-19 diagnostic testing, further vital signs assessment, and/or treatment) and/or hospital care. To evaluate algorithm performance, the cohort will be tested for COVID-19 antibodies at the end of follow-up. COVID-19 seropositivity in the intervention cohort will be compared seropositivity in a control population of 20,000 individuals drawn from the same populations using the application only. Thus, this project will deliver a large body of information on COVID-19 PCR testing and antibodies that can be used to develop additional diagnostics and therapeutics in addition to validating remote vital signs and self-reported symptoms monitoring systems.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101005177 |
| Start date: | 01-07-2020 |
| End date: | 31-12-2022 |
| Total budget - Public funding: | 10 329 253,00 Euro - 9 592 028,00 Euro |
Cordis data
Original description
In this project, we will evaluate the use and performance of a CE-marked device (wearable), which uses sensors to measure breathing rate, pulse rate, skin temperature, and heart rate variability for the purpose of early detection and monitoring of COVID-19 in general and high-risk populations. At the same time, a mobile application will be used to track participant-reported symptoms. A prospective, observational study will follow 13,000 individuals from the general population and 7,000 high-risk individuals wearing the device and responding to participant self-report parameters via a purpose-designed app. Based on this data, an algorithm will indicate which individuals likely require general practitioner (GP) care (for COVID-19 diagnostic testing, further vital signs assessment, and/or treatment) and/or hospital care. To evaluate algorithm performance, the cohort will be tested for COVID-19 antibodies at the end of follow-up. COVID-19 seropositivity in the intervention cohort will be compared seropositivity in a control population of 20,000 individuals drawn from the same populations using the application only. Thus, this project will deliver a large body of information on COVID-19 PCR testing and antibodies that can be used to develop additional diagnostics and therapeutics in addition to validating remote vital signs and self-reported symptoms monitoring systems.Status
CLOSEDCall topic
IMI2-2020-21-01Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Search
